Cancer

Title
A Study Comparing the Combination of Gemcitabine, Cisplatin and Bevacizumab on Transitional Cell Carcinoma of the Urinary Tract
Trial Number
202213
Number of Participants
500
Principal Investigator

Ellen R. Gaynor

M.D.
Hematology/Oncology
Professor
Eligibility

Adults = 18 years old must have:
•Histologically documented metastatic or unresectable transitional cell carcinoma of the urinary tract, with progressive metastatic or locally advanced disease.
•ECOG performance status 0-1
•Additional requirements in section 4 of the protocol

Purpose

The purpose of this study is to see what effects, good and/or bad, the combination of gemcitabine, cisplatin and bevacizumab has on participants and their cancer.

Enrollment

(708) 327 - 3101

MORE CLINICAL TRIALS

Clinical Trials

For more information call (888) LUHS-888.